Other Events · Jul 14, 2026

Crescent Biopharma, Inc. reported preliminary unaudited cash and cash equivalents of approximately $171.6 million as…

CBIOCrescent Biopharma, Inc.

Crescent Biopharma, Inc. reported preliminary unaudited cash and cash equivalents of approximately $171.6 million as of June 30, 2026. The company is a biopharmaceutical company focused on developing and commercializing biopharmaceutical products.